Open AccessIn vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension
Author(s) -
Ian Morecroft,
Lei Pang,
Maria Baranowska,
Margaret Nilsen,
Lynn Loughlin,
Yvonne Dempsie,
Caroline Millet,
Margaret R. MacLean
Publication year - 2009
Publication title -
cardiovascular research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.774
H-Index - 219
eISSN - 1755-3245
pISSN - 0008-6363
DOI - 10.1093/cvr/cvp306
Subject(s) - pulmonary artery , in vivo , serotonin , antagonist , vasoconstriction , pulmonary hypertension , serotonin transporter , receptor antagonist , receptor , pharmacology , medicine , endocrinology , biology , microbiology and biotechnology
A mechanism for co-operation between the serotonin (5-hydroxytryptamine, 5-HT) transporter and 5-HT1B receptor in mediating pulmonary artery vasoconstriction and proliferation of pulmonary artery smooth muscle cells has been demonstrated in vitro. Here we determine, for the first time, the in vivo effects of a combined 5-HT1B receptor/serotonin transporter antagonist (LY393558) with respect to the development of pulmonary arterial hypertension (PAH) and its in vitro effects in human pulmonary artery smooth muscle cells (hPASMCs) derived from idiopathic PAH (IPAH) patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom